USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030
Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030
The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model
RELEASE DATE
21-Mar-2025
21-Mar-2025
REGION
Global
Global
Deliverable Type
Market Research
Market Research
Research Code: PFRO-01-00-00-00
SKU: HC_2025_33413
$4,950.00
In stock
SKU
HC_2025_33413
As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial turnarounds and improved time to market. In this context, the global CRO industry was valued at $66.39 billion in 2024, and it is expected to register a CAGR of 10.7% from 2024 to 2030, reaching $122.13 billion in 2030. Across the global pharma market, the overall CRO outsourcing penetration rate ranges from 45%-50%, depending on the service type.
In addition to full-service CROs operating in the global CRO industry, there is a surge of peripheral service-focused CROs, also referred to as specialized/niche CROs. These companies exclusively focus on supportive functions, including biostatistics, lab testing, pharmacovigilance, post-market surveillance, and investigational product (IP) management. These activities support the core clinical research functions, ensuring timely completion and required outcomes.
As the emphasis on biologics drug development grows, small-to-mid-sized and emerging biopharma companies are contributing more than 50% of the pipelines. Apart from trial-related services, such as patient recruitment, site selection and management, and investigator recruitment, clinical trial peripheral services, such as pharmacovigilance, safety testing, central lab services, medical writing, IP management, data management, and biostatistics, have been gaining traction, with pharma sponsors increasingly outsourcing these specific activities to CROs.
This is leading to the extensive use of the functional service provider (FSP) model targeting specific trial-related ancillary or peripheral activities. Though a significant share of the clinical pipeline is contributed by small-to-mid-sized and emerging biopharma companies, the need for peripheral services through FSP models is expected to witness a sharp rise, especially from large pharma companies looking to optimize trial costs.
Moreover, the industry will witness a shift to a hybrid FSO/FSP model, as companies aim to augment their clinical trial activities through better risk mitigation. As a result, these companies will look for outsourcing partners to meet their clinical research needs, paving the way for both full-service outsourcing and FSP models, which focus on supporting peripheral activities, such as analytical testing, data management, and biostatistics.
Key Issues Addressed
- What are the general industry trends? What are the specific trends for peripheral activities within clinical trials?
- What are the key drivers triggering large-scale outsourcing of clinical development?
- What key emerging business models are providing a competitive advantage to pharma sponsors? How is this trend supporting industry convergence?
- Who are the leading participants driving market growth?
- What is the growth opportunity for small-to-mid-sized CRO companies amidst 1,500+ competitors?
- How is the application of technology supporting the growth of the CRO peripheral activities landscape? Which are the fastest-growing peripheral activities in the CRO industry?
Author: Aarti Siddhesh Chitale
Scope of Analysis
Segmentation
CRO Peripheral Services—Defining Key Activities Across Peripheral Services
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Clinical Contract Peripheral Services Industry
Market Trend Analysis
Contract Peripheral Services—Vendor Ecosystem
CRDMO—The New Normal in Early-stage Drug Development
Evolving Partnership Models Across the CRO Market
FSP Model Types
FSP Model Outlook
Key Competitors—By Regions
Investment Trends
Portfolio Expansion with M&As
Project-specific CRO Expertise With Strategic Partnerships
In-house Investments for Long-term Growth
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Assumptions
Market Forecast—Limitations and Caveats
Revenue Forecast Methodology
Revenue Forecast
Revenue Forecast Analysis
Percent Revenue Share by Clinical Development Phase
Revenue Forecast Analysis by Clinical Development Phase
Revenue Share
Revenue Share Analysis
Revenue Forecast by Region
Percent Revenue Forecast by Region
Revenue Forecast Analysis—North America
Revenue Forecast Analysis—Europe
Revenue Forecast Analysis—APAC
Revenue Forecast Analysis—LATAM and Caribbean
Revenue Forecast Analysis—MEA
Revenue Forecast by Peripheral Services Versus Core Services
Percent Revenue Forecast by Peripheral Services Versus Core Services
Revenue Forecast by Peripheral Service Segments
Revenue Forecast Analysis
Central Lab Testing Services
Central Lab Testing Services—Revenue Forecast
Central Lab Testing Services—Revenue Forecast by Region
Central Lab Testing Services—Revenue Forecast Discussion
Biostatistics Services
Biostatistics Services—Revenue Forecast
Biostatistics Services—Revenue Forecast by Region
Biostatistics Services—Revenue Forecast Discussion
Data Management Services
Data Management Services—Revenue Forecast
Data Management Services—Revenue Forecast by Region
Data Management Services—Revenue Forecast Discussion
Pharmacovigilance and Safety Testing Services
Pharmacovigilance and Safety Testing Services—Revenue Forecast
Pharmacovigilance and Safety Testing Services—Revenue Forecast by Region
Pharmacovigilance and Safety Testing Services—Revenue Forecast Discussion
IP Management Services
IP Management Services—Revenue Forecast
IP Management Services—Revenue Forecast by Region
IP Management Services—Revenue Forecast Discussion
Medical Writing Services
Medical Writing Services—Revenue Forecast
Medical Writing Services—Revenue Forecast by Region
Medical Writing Services—Revenue Forecast Discussion
Regulatory and Medical Affairs Services
Regulatory and Medical Affairs Services—Revenue Forecast
Regulatory and Medical Affairs Services—Revenue Forecast by Region
Regulatory and Medical Affairs Services—Revenue Forecast Discussion
Growth Opportunity 1: Medical Co-pilot-powered Clinical Trial Data Management
Growth Opportunity 2: Central Lab Services for Biotechnology Companies in Australia
Growth Opportunity 3: Customized Services for Regulatory and Medical Affairs
Growth Opportunity 4: Pharmacovigilance-as-a-Service
Growth Opportunity 5: Customer-centric Partnership Models for Peripheral Service Outsourcing
Benefits and Impacts of Growth Opportunities
Next Steps
List of Exhibits
Legal Disclaimer
List of Figures
- Pharmaceutical Clinical Contract Peripheral Services: Growth Metrics, Global, 2024
- Pharmaceutical Clinical Contract Peripheral Services: Growth Drivers, Global, 2025–2030
- Pharmaceutical Clinical Contract Peripheral Services: Growth Restraints, Global, 2025–2030
- Cost Assumptions: Cost of Trial Per Patient ($), Global, 2024
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Clinical Development Phase, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Share by Clinical Development Phase, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Share of Top Participants, Global, 2023
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Region, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Forecast by Region, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Peripheral Services Versus Core Services, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Forecast by Peripheral Services Versus Core Services, Global, 2022–2030
- Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Peripheral Service Segments, Global, 2022–2030
- Central Lab Testing Services: Revenue Forecast, Global, 2022–2030
- Central Lab Testing Services: Revenue Forecast by Region, Global, 2022–2030
- Biostatistics Services: Revenue Forecast, Global, 2022–2030
- Biostatistics Services: Revenue Forecast by Region, Global, 2022–2030
- Data Management Services: Revenue Forecast, Global, 2022–2030
- Data Management Services: Revenue Forecast by Region, Global, 2022–2030
- Pharmacovigilance and Safety Testing Services: Revenue Forecast, Global, 2022–2030
- Pharmacovigilance and Safety Testing Services: Revenue Forecast by Region, Global, 2022–2030
- IP Management Services: Revenue Forecast, Global, 2022–2030
- IP Management Services: Revenue Forecast by Region, Global, 2022–2030
- Medical Writing Services: Revenue Forecast, Global, 2022–2030
- Medical Writing Services: Revenue Forecast by Region, Global, 2022–2030
- Regulatory and Medical Affairs Services: Revenue Forecast, Global, 2022–2030
- Regulatory and Medical Affairs Services: Revenue Forecast by Region, Global, 2022–2030
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial turnarounds and improved time to market. In this context, the global CRO industry was valued at $66.39 billion in 2024, and it is expected to register a CAGR of 10.7% from 2024 to 2030, reaching $122.13 billion in 2030. Across the global pharma market, the overall CRO outsourcing penetration rate ranges from 45%-50%, depending on the service type.
In addition to full-service CROs operating in the global CRO industry, there is a surge of peripheral service-focused CROs, also referred to as specialized/niche CROs. These companies exclusively focus on supportive functions, including biostatistics, lab testing, pharmacovigilance, post-market surveillance, and investigational product (IP) management. These activities support the core clinical research functions, ensuring timely completion and required outcomes.
As the emphasis on biologics drug development grows, small-to-mid-sized and emerging biopharma companies are contributing more than 50% of the pipelines. Apart from trial-related services, such as patient recruitment, site selection and management, and investigator recruitment, clinical trial peripheral services, such as pharmacovigilance, safety testing, central lab services, medical writing, IP management, data management, and biostatistics, have been gaining traction, with pharma sponsors increasingly outsourcing these specific activities to CROs.
This is leading to the extensive use of the functional service provider (FSP) model targeting specific trial-related ancillary or peripheral activities. Though a significant share of the clinical pipeline is contributed by small-to-mid-sized and emerging biopharma companies, the need for peripheral services through FSP models is expected to witness a sharp rise, especially from large pharma companies looking to optimize trial costs.
Moreover, the industry will witness a shift to a hybrid FSO/FSP model, as companies aim to augment their clinical trial activities through better risk mitigation. As a result, these companies will look for outsourcing partners to meet their clinical research needs, paving the way for both full-service outsourcing and FSP models, which focus on supporting peripheral activities, such as analytical testing, data management, and biostatistics.
In addition to full-service CROs operating in the global CRO industry, there is a surge of peripheral service-focused CROs, also referred to as specialized/niche CROs. These companies exclusively focus on supportive functions, including biostatistics, lab testing, pharmacovigilance, post-market surveillance, and investigational product (IP) management. These activities support the core clinical research functions, ensuring timely completion and required outcomes.
As the emphasis on biologics drug development grows, small-to-mid-sized and emerging biopharma companies are contributing more than 50% of the pipelines. Apart from trial-related services, such as patient recruitment, site selection and management, and investigator recruitment, clinical trial peripheral services, such as pharmacovigilance, safety testing, central lab services, medical writing, IP management, data management, and biostatistics, have been gaining traction, with pharma sponsors increasingly outsourcing these specific activities to CROs.
This is leading to the extensive use of the functional service provider (FSP) model targeting specific trial-related ancillary or peripheral activities. Though a significant share of the clinical pipeline is contributed by small-to-mid-sized and emerging biopharma companies, the need for peripheral services through FSP models is expected to witness a sharp rise, especially from large pharma companies looking to optimize trial costs.
Moreover, the industry will witness a shift to a hybrid FSO/FSP model, as companies aim to augment their clinical trial activities through better risk mitigation. As a result, these companies will look for outsourcing partners to meet their clinical research needs, paving the way for both full-service outsourcing and FSP models, which focus on supporting peripheral activities, such as analytical testing, data management, and biostatistics.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Pharma contract services market |
| Keyword 2 | Pharma industry growth insights |
| Keyword 3 | CRO peripheral services report |
| List of Charts and Figures | Pharmaceutical Clinical Contract Peripheral Services: Growth Metrics, Global, 2024~ Pharmaceutical Clinical Contract Peripheral Services: Growth Drivers, Global, 2025–2030~ Pharmaceutical Clinical Contract Peripheral Services: Growth Restraints, Global, 2025–2030~ Cost Assumptions: Cost of Trial Per Patient ($), Global, 2024~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Clinical Development Phase, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Share by Clinical Development Phase, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Share of Top Participants, Global, 2023~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Region, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Forecast by Region, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Peripheral Services Versus Core Services, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Percent Revenue Forecast by Peripheral Services Versus Core Services, Global, 2022–2030~ Pharmaceutical Clinical Contract Peripheral Services: Revenue Forecast by Peripheral Service Segments, Global, 2022–2030~ Central Lab Testing Services: Revenue Forecast, Global, 2022–2030~ Central Lab Testing Services: Revenue Forecast by Region, Global, 2022–2030~ Biostatistics Services: Revenue Forecast, Global, 2022–2030~ Biostatistics Services: Revenue Forecast by Region, Global, 2022–2030~ Data Management Services: Revenue Forecast, Global, 2022–2030~ Data Management Services: Revenue Forecast by Region, Global, 2022–2030~ Pharmacovigilance and Safety Testing Services: Revenue Forecast, Global, 2022–2030~ Pharmacovigilance and Safety Testing Services: Revenue Forecast by Region, Global, 2022–2030~ IP Management Services: Revenue Forecast, Global, 2022–2030~ IP Management Services: Revenue Forecast by Region, Global, 2022–2030~ Medical Writing Services: Revenue Forecast, Global, 2022–2030~ Medical Writing Services: Revenue Forecast by Region, Global, 2022–2030~ Regulatory and Medical Affairs Services: Revenue Forecast, Global, 2022–2030~ Regulatory and Medical Affairs Services: Revenue Forecast by Region, Global, 2022–2030~ |
| Podcast | No |
| Predecessor | PDC6-01-00-00-00 |
| WIP Number | PFRO-01-00-00-00 |